Treatment
Anthracycline clinical trials
We’re tracking 35 recruiting studies that include Anthracycline, each written for real people, not researchers, below.
Recruiting studies
- NCT07528586Recruiting
Heart Imaging Study During Cancer Drug Treatment
This study uses heart imaging scans and blood tests to check if a common cancer drug (anthracycline) is affecting your heart during treatment. Early detection might help doctors protect your heart health.
StuttgartAges 18 years+ - NCT07426913Recruiting
Virtual reality heart health for breast cancer survivors
This trial tests if a virtual reality program can help breast cancer survivors taking certain chemotherapies improve their heart health. It's for people currently receiving trastuzumab or anthracycline-based treatment, along with immunotherapy, for their first breast cancer diagnosis.
Richmond, VirginiaAges 18 years+ - NCT07245069RecruitingPhase 2
Can dapagliflozin protect the heart during breast cancer chemo?
This trial tests if the drug dapagliflozin can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. It aims to see if taking the drug during chemo helps keep your heart healthy.
LjubljanaAges 18 years+ - NCT06898320Recruiting
Heart health study for kids starting a type of chemotherapy
This study checks how a common chemotherapy drug (anthracycline) affects the heart in children. It will monitor heart function during treatment to help protect young patients.
Trieste, ItalyAges birth–18 years - NCT06443645Recruiting
Protecting the heart during breast cancer treatment
This trial tests whether a diabetes medicine (SGLT2 inhibitor) can prevent heart damage caused by a common chemotherapy drug (anthracycline) in people with early-stage breast cancer. If you are newly diagnosed and about to start chemotherapy or have surgery, this study may be for you.
StrasbourgAges 18 years+ - NCT05223413Recruiting
Remote arm treatment to protect the heart during chemo
This trial studies whether a simple “remote conditioning” treatment on the arm can help protect the heart while you receive chemotherapy that includes anthracyclines. If you’re at higher risk for heart damage from chemo, this may reduce risk and help monitor heart function over time.
AarhusAges 18–99 - NCT07878351Recruiting
Blood test to guide treatment for large B-cell lymphoma
This study looks at whether a blood test can help doctors understand and monitor large B-cell lymphoma during treatment. It may help guide decisions about your care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07743190RecruitingPhase 2
Lighter chemo for early-stage triple-negative breast cancer with high immune cells
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
Syracuse, New YorkAges 18 years+ - NCT07867600Recruiting
Lower-dose chemo for children with new leukemia
This trial tests a lower starting dose of chemotherapy for children newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. The goal is to see if a reduced dose is still effective and safer for children.
Asyut, Asyut GovernorateAges Up to 18 years - NCT06214195RecruitingPhase 3
Shengmai San to prevent heart damage from breast cancer therapy
This trial tests if a traditional Chinese medicine called Shengmai San can protect the heart during chemotherapy and targeted therapy for HER2-positive breast cancer. Patients take the supplement alongside standard treatment to see if it reduces the risk of heart problems.
Hangzhou, ZhejiangAges 18 years+ - NCT06282796Recruiting
Early heart risk monitoring for breast cancer chemo
This study tests a method to predict and warn about heart damage from a common type of breast cancer chemotherapy. If you have HER2-positive breast cancer and will receive anthracycline drugs, this trial may help monitor your heart health.
Fuzhou, FujianAges 18–80 - NCT06297512RecruitingPhase 2
Testing chemotherapy after radiation for young patients with glioblastoma
This trial tests whether a type of chemotherapy called anthracycline can help young patients with glioblastoma when given after radiation therapy. It aims to see if this treatment improves outcomes for patients aged 3 to 30.
FlorenceAges 3–30 - NCT07672262RecruitingPhase 2
VA maintenance before transplant for intermediate-risk AML
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
Suzhou, JiangsuAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT06711185RecruitingPhase 3
Can dapagliflozin protect breast cancer patients' hearts during chemo?
This trial tests if a diabetes medicine called dapagliflozin (also known as Farxiga) can protect the hearts of women with breast cancer while they receive anthracycline chemotherapy. You would take the medicine and have heart MRI scans to see if it helps prevent heart damage.
Campinas, São PauloAges 18 years+ - NCT06304857RecruitingPhase 3
Protecting the heart with dapagliflozin during breast cancer treatment
This trial tests if the diabetes drug dapagliflozin can protect the heart in people with breast cancer receiving a type of chemotherapy called anthracyclines. You may be able to join if you are between 18 and 80, have stage I-III breast cancer, and are about to start anthracycline treatment within the next 60 days.
Wroclaw, Lower Silesian VoivodeshipAges 18–80 - NCT07548710RecruitingPhase 2
SA plus X for newly diagnosed AML
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06774326Recruiting
Spectral CT to check for heart damage from lymphoma treatment
This study uses a special type of CT scan called spectral CT to see if chemotherapy drugs called anthracyclines can cause heart damage in people with certain lymphomas. The goal is to catch any heart problems early by imaging the heart before, during, and after treatment.
BolognaAges 18 years+ - NCT06766266RecruitingPhase 1
Irinotecan and Epirubicin for recurring bladder cancer
This trial tests a combination of two chemotherapy drugs (irinotecan and epirubicin) for people whose bladder cancer has come back after prior treatment with a similar drug. The goal is to see if this combination can help shrink or control the cancer.
ChongqingAges 18 years+ - NCT07191730Recruiting
Heart risk prediction for cancer patients on certain chemotherapies
This trial uses a special scoring system (ML Score) to predict if you might develop heart problems while receiving anthracycline chemotherapy or HER2-targeted therapies. It helps doctors decide on the best heart monitoring plan before starting treatment.
CaenAges 18 years+ - NCT07178171RecruitingPhase 1
QL1706 + short chemo for early triple-negative breast cancer
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
Xi'an, ShaanxiAges 18–70 - NCT07070765Recruiting
Study on dapagliflozin to protect the heart during breast cancer chemo
This trial tests if a heart-protecting drug called dapagliflozin can help prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. It may be an option if you have low to medium heart risk factors.
Aberdeen, AberdeenshireAges 18–70 - NCT06955702Recruiting
Cryotherapy to Prevent Eyelash Loss from Chemo
This trial tests if cooling the eyelids during chemotherapy can prevent eyelash loss in women with newly diagnosed breast cancer. It is for those who have not yet started treatment.
Santander, CantabriaAges 18 years+ - NCT07060001RecruitingPhase 2
Comparing two leukemia treatments using a blood test
This trial compares two standard treatments for newly diagnosed acute myeloid leukemia (AML) to see if a simple blood test can help predict how well each treatment works. The goal is to find the best treatment approach for each person.
Houston, TexasAges 18 years+
What Anthracycline is being studied for
Conditions with recruiting Anthracycline studies.
Common questions
- Are there clinical trials studying Anthracycline?
- Yes. Clin2 currently lists 35 recruiting studies that include Anthracycline, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Anthracycline trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Anthracycline an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Anthracycline or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.